CRSP · XBRL financial data

CRISPR Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CRSP's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	year only	1	1	1	36*	1	1	1	1*	1	10	13
Research and development	95*	76	80	82	82*	72	70	59	84*	69	67	72
General and administrative	16*	18	19	17	18*	19	19	17	18*	17	18	18
Total operating expenses	132*	141	152	111	100*	149	230	133	156*	132	127	143
Operating income (loss)	70*	(141)	(151)	(110)	(65)*	(148)	(229)	(132)	(155)*	(130)	(117)	(130)
Interest income	year only	—	—	—	year only	—	—	—	—	—	—	—
Interest expense	—	—	—	—	—	0	0	0	—	1	3	3
Other income (expense)	20*	25	26	25	28*	14	22	26	25*	8	27	19
Income tax expense (benefit)	0*	1	1	1	1*	1	1	1	1*	1	1	0
Net income (loss)	89*	(117)	(126)	(86)	(37)*	(136)	(209)	(106)	(131)*	(123)	(91)	(111)
Earnings per share, basic USD per share	1.12*	(1.43)	(1.49)	(1.01)	(0.44)*	(1.58)	(2.40)	(1.17)	(1.37)*	(1.28)	(0.94)	(1.15)
Earnings per share, diluted USD per share	1.12*	(1.43)	(1.49)	(1.01)	(0.44)*	(1.58)	(2.40)	(1.17)	(1.37)*	(1.28)	(0.94)	(1.15)
Weighted average shares, basic millions of shares	80*	82	85	85	85*	86	87	91	95*	96	97	97
Weighted average shares, diluted millions of shares	80*	82	85	85	85*	86	87	91	95*	96	97	97

Fiscal quarters (CRSP's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	389	707	484	226	298	235	194	286	348	423	291	192
Marketable securities	1,304	1,401	1,517	1,710	1,606	1,620	1,528	1,629	1,628	2,018	2,073	2,081
Marketable securities, non-current	2	0	11	0	0	0	0	28	0	0	0	4
Accounts receivable	200	0	0	0	25	0	0	0	0	—	—	—
Prepaid and other current assets	14	11	9	8	8	12	12	13	10	7	7	13
Total current assets	1,908	2,120	2,010	1,944	1,937	1,868	1,734	1,929	1,986	2,448	2,372	2,285
Property and equipment, net	152	147	143	139	134	129	125	121	116	112	108	104
Right-of-use asset	154	151	149	146	143	140	138	135	132	129	126	123
Total assets	2,230	2,439	2,340	2,256	2,242	2,166	2,030	2,245	2,265	2,726	2,651	2,556
Accounts payable	38	16	9	16	15	13	10	12	11	14	11	21
Accrued liabilities	45	76	92	47	41	85	74	84	89	75	70	82
Total current liabilities	109	119	128	90	88	119	104	119	149	136	133	141
Lease liability, non-current	223	219	215	211	206	202	197	193	188	184	179	174
Total liabilities	347	355	359	316	310	337	319	329	343	911	904	908
Accumulated deficit	(1,000)	(1,116)	(1,243)	(1,329)	(1,366)	(1,502)	(1,710)	(1,817)	(1,948)	(2,070)	(2,162)	(2,273)
Total stockholders' equity	1,883	2,084	1,981	1,940	1,932	1,829	1,711	1,916	1,922	1,815	1,747	1,648
Total liabilities and equity	2,230	2,439	2,340	2,256	2,242	2,166	2,030	2,245	2,265	2,726	2,651	2,556
Common shares outstanding (cover page) millions of shares	80	85	85	85	86	86	91	95	96	96	97	97

Fiscal quarters (CRSP's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	89*	(117)	(126)	(86)	(37)*	(136)	(209)	(106)	(131)*	(123)	(91)	(111)
Stock-based compensation	18*	19	24*	22*	22*	20	18*	17*	18*	16	17*	18*
Depreciation and amortization	5*	5	5*	5*	5*	5	5*	4*	6*	4	4*	4*
Net cash from operating activities	(96)*	110	(96)*	(107)*	(50)*	(54)	(114)*	(85)*	(93)*	(109)	(83)*	(90)*
Purchases of property and equipment	1*	1	1*	0*	0*	0	0*	0*	1*	1	1*	0*
Net cash from investing activities	(81)*	(98)	(127)*	(162)*	106*	(20)	70*	(119)*	37*	(411)	(56)*	(14)*
Proceeds from issuing common stock	33*	281	(1)*	6*	15*	9	(0)*	278*	111*	(1)	0*	0*
Net cash from financing activities	39*	306	(0)*	10*	17*	11	2*	297*	116*	592	7*	4*
Net change in cash	(139)*	318	(223)*	(259)*	73*	(63)	(42)*	93*	61*	72	(132)*	(99)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
CRISPR Therapeutics	192	13	(90)*	97.0M	24.0 quarters	Q3 FY26 10-QSep 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Merus	367	12	(85)*	75.8M	7.5 quarters	Q3 FY25 10-QSep 30, 2025
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.